{
    "clinical_study": {
        "@rank": "153123", 
        "arm_group": [
            {
                "arm_group_label": "Participants with Severe Renal Insufficiency: Part 1/Panel A", 
                "arm_group_type": "Experimental", 
                "description": "Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein."
            }, 
            {
                "arm_group_label": "Participants with Moderate Renal Insufficiency: Part 1/Panel B", 
                "arm_group_type": "Experimental", 
                "description": "Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein."
            }, 
            {
                "arm_group_label": "Healthy Control Participants: Part 1/Panel C", 
                "arm_group_type": "Experimental", 
                "description": "Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein."
            }, 
            {
                "arm_group_label": "Participants with Severe Renal Insufficiency: Part 2/Panel D", 
                "arm_group_type": "Experimental", 
                "description": "Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush."
            }, 
            {
                "arm_group_label": "Participants with Moderate Renal Insufficiency: Part 2/Panel E", 
                "arm_group_type": "Experimental", 
                "description": "Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush."
            }, 
            {
                "arm_group_label": "Healthy Control Participants: Part 2/Panel F", 
                "arm_group_type": "Experimental", 
                "description": "Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the plasma pharmacokinetics of a single 4 mg/kg\n      intravenous (IV) dose of sugammadex in participants with moderate and severe renal\n      insufficiency compared to that in participants with normal renal function. The study\n      consists of two parts. In Part 1, participants with renal insufficiency and healthy\n      participants will be administered study drug by IV bolus injection into a peripheral vein.\n      In Part 2, participants with renal insufficiency and healthy participants will be\n      administered study drug as an IV bolus into a peripheral vein, through an IV catheter\n      connected to IV tubing with injection port. Subjects who participate in Part 1 of study may\n      be enrolled in Part 2, which would reduce the overall number of participants enrolled for\n      the study."
        }, 
        "brief_title": "Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Renal Insufficiency", 
            "Renal Impairment"
        ], 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All Participants:\n\n          -  Body Mass Index \u226518 to \u226440 kg/m^2\n\n          -  Females of childbearing potential must either be sexually inactive (abstinent) for 14\n             days prior to dosing and throughout the study or are using an acceptable birth\n             control method\n\n          -  Females of non-childbearing potential must have undergone a sterilization procedure\n             at least 6 months prior to dosing or are postmenopausal with amenorrhea for at least\n             1 year prior to dosing and have follicle stimulating hormone (FSH) serum levels\n             consistent with postmenopausal status\n\n          -  Male subjects must agree not to donate sperm from dosing until 90 days after dosing\n\n        Participants with Moderate or Severe Renal Insufficiency:\n\n          -  Health of participant is stable based on medical history, laboratory tests and other\n             assessments\n\n          -  Clinical diagnosis of impaired stable renal function, and a creatinine clearance\n             (CLcr) of <30 mL/min and not on hemodialysis for severe renal insufficiency\n             participants, or 30 to <50 mL/min for moderate renal insufficiency participants\n\n          -  No clinically significant change in renal status for at least 1 month prior to\n             dosing, and is not currently or has not previously been on hemodialysis\n\n        Healthy Control Participants:\n\n          -  Participant is medically healthy based on laboratory tests and other assessments\n\n          -  Age of the individual healthy participants in Part 1 of the study is aimed to be\n             within the range of the mean age \u00b1 approximately 15 years of all participants with\n             renal impairment in Part 1 of the study combined; this approach will also be applied\n             with respect to age of participants in Part 2 of the study\n\n          -  CLcr \u226580 mL/min\n\n        Exclusion Criteria:\n\n        All Participants:\n\n          -  Mentally or legally incapacitated, significant emotional problems at screening or\n             expected during the conduct of the study or history of a clinically significant\n             psychiatric disorder over the last 5 years\n\n          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,\n             hematological, gastrointestinal, endocrine, immunologic, dermatologic, or\n             neurological disease whose current condition is considered unstable\n\n          -  History or presence of alcoholism and drug abuse within the past 6 months\n\n          -  History or presence of hypersensitivity or idiosyncratic reaction to the study\n             medication or related compounds\n\n          -  Female participants who are pregnant or lactating\n\n          -  Positive results for the urine or saliva drug screen, or for the urine or breath\n             alcohol screen\n\n          -  Positive results at screening for human immunodeficiency virus (HIV), hepatitis B\n             surface antigen (HBsAg) or hepatitis C virus (HCV)\n\n          -  Regular user of any medication (including over the counter) that would significantly\n             alter renal function (e.g., cimetidine)\n\n          -  Donation of blood or significant blood loss within 56 days prior to dosing, or\n             donation of plasma within 7 days prior to dosing\n\n          -  Participation in another clinical trial within 28 days prior to dosing\n\n          -  No participant may be enrolled more than once within Part 1.  Subjects who\n             participate in Part 1 of study may be enrolled in Part 2, but participants within\n             Part 2 are not to be enrolled more than once in Part 2\n\n        Healthy Control Participants:\n\n          -  Participant has had a renal transplant or has had nephrectomy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011490", 
            "org_study_id": "8616-105"
        }, 
        "intervention": {
            "arm_group_label": [
                "Participants with Severe Renal Insufficiency: Part 1/Panel A", 
                "Participants with Moderate Renal Insufficiency: Part 1/Panel B", 
                "Healthy Control Participants: Part 1/Panel C", 
                "Participants with Severe Renal Insufficiency: Part 2/Panel D", 
                "Participants with Moderate Renal Insufficiency: Part 2/Panel E", 
                "Healthy Control Participants: Part 2/Panel F"
            ], 
            "description": "sugammadex 4 mg/kg IV bolus", 
            "intervention_name": "sugammadex", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hialeah", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33014"
                }, 
                "name": "Investigational Site 001"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve from time zero to the last measurable concentration (AUC0-last) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "AUC from time zero to infinity (AUC0-\u221e) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Percent of AUC0-\u221e that was extrapolated (AUC%extrap) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Total clearance (CL) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Maximum observed plasma concentration (Cmax) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Time to maximum observed plasma concentration (Tmax) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Time of the last measurable plasma concentration (tlast) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Apparent first-order terminal elimination rate constant (\u03bbz) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Apparent first-order terminal elimination half-life (T1/2) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Volume of distribution during the terminal elimination phase (Vz) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Mean residence time (MRT) of unchanged drug in the systemic circulation following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Effective half-life (t1/2eff) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }, 
            {
                "measure": "Apparent volume of distribution estimated at steady-state (Vss) following a single IV dose of sugammadex", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours for participants with normal renal function, up to 28 days for participants with moderate renal insufficiency and up to 35 days for participants with severe renal insufficiency"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011490"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}